Dana–Farber Cancer Institute

Harbinger Health Begins New Clinical Study in Individuals at High Risk for Cancer

Retrieved on: 
Tuesday, December 5, 2023

CAMBRIDGE, Mass., Dec. 5, 2023 /PRNewswire/ -- Harbinger Health ("Harbinger," "the Company"), a biotechnology company pioneering new technologies to fundamentally change cancer screening and detection, announced today a research agreement with the Hale Family Center for Pancreatic Cancer Research at Dana-Farber Cancer Institute to advance the Company's technology for early-stage multi-cancer detection.

Key Points: 
  • With this agreement, Harbinger and the Hale Family Center will jointly conduct a clinical study of participants at high risk for cancer due to a family history of pancreatic cancer.
  • Harbinger will test its proprietary blood-based cancer screening platform using blood samples from participants over a period of 30 months to model their risk level for the disease.
  • Further, a personal or family history of pancreatic cancer carries an increased risk for other types of cancer, most notably breast cancer and cancers of organs in the gastrointestinal tract.
  • Ultimately, we hope to one day provide high-risk individuals and medical providers with advanced tools to assess risk and detect multiple cancers before they are visible or symptomatic."

Powered by Its Industry-Leading Comprehensive Multi-Omic Database, Caris Life Sciences to Showcase Research at the 2023 San Antonio Breast Cancer Symposium

Retrieved on: 
Monday, December 4, 2023

IRVING, Texas, Dec. 4, 2023 /PRNewswire/ -- Caris Life Sciences®(Caris), the leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition using molecular science and AI, today announced that the company and collaborators within the Caris Precision Oncology Alliance™ (POA) will collectively present findings at the San Antonio Breast Cancer Symposium (SABCS) that illustrate the potential impact of molecular profiling on the treatment of breast cancer. The findings demonstrate the power of Caris' comprehensive clinico-genomic database that enables novel insights into cancer that could have profound effects on a patient's diagnosis, prognosis, care plan, and response to treatment. SABCS is being held December 5-9, 2023 (Booth #1433) in San Antonio, Texas.

Key Points: 
  • "The San Antonio Breast Cancer Symposium continues to be the premiere conference for breast cancer research," said George W. Sledge, Jr. , MD, Executive Vice President and Chief Medical Officer of Caris.
  • "As part of our continuing commitment to the breast cancer community, Caris is proud to share important clinical/translational research created with our academic partners on important breast cancer questions."
  • The results of this analysis indicate that male breast cancer has differential molecular and immune features compared to female breast cancer.
  • Caris will present additional data from studies demonstrating the critical role of precision medicine and molecular profiling in the treatment of breast cancer.

BrainSpec Receives Full FDA Clearance to Begin Using AI-Backed Solution for Non-Invasive Brain Chemistry Measurement

Retrieved on: 
Monday, November 27, 2023

BOSTON, Nov. 27, 2023 /PRNewswire/ -- BrainSpec, the comprehensive software platform enabling virtual biopsies of the brain, has been awarded clearance by the FDA to begin using their Magnetic Resonance Spectroscopy (MRS) platform to provide non-invasive measurement of brain chemistry to support the diagnostic process in the most common brain-related illnesses, including Alzheimer's disease, multiple sclerosis, epilepsy, brain tumors, and more. This marks the first-time software using a reference database of brain chemistry has been included in an FDA clearance.

Key Points: 
  • First-ever brain chemistry database will allow clinicians to quickly infer brain biomarker data to support the diagnostic process in conditions such as Alzheimer's Disease and Traumatic Brain Injury.
  • BrainSpec Core™ shows 85% sensitivity and 90% specificity in detecting 2-Hydroxyglutarate, an oncometabolite present in low-grade gliomas.
  • This marks the first-time software using a reference database of brain chemistry has been included in an FDA clearance.
  • By using non-invasive imaging, BrainSpec Core™ measures concentrations of chemicals in the brain in order to create a virtual biopsy using standard MRI scanners.

CARsgen Announces Formation of its Clinical Advisory Board

Retrieved on: 
Monday, November 20, 2023

SHANGHAI, Nov. 20, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces the formation of its Clinical Advisory Board.

Key Points: 
  • SHANGHAI, Nov. 20, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces the formation of its Clinical Advisory Board.
  • This highly regarded panel of experts will provide invaluable guidance and insights for the global clinical development of company's innovative product candidates.
  • "As we embark on this exciting journey to advance our differentiated CAR T-cell therapies, I am delighted to welcome our esteemed Clinical Advisory Board members.
  • The formation of this Clinical Advisory Board marks a significant step forward for CARsgen as it continues to pioneer CAR T-cell therapies with the potential to transform cancer treatment.

New Analyses from Pivotal Phase 3 INDIGO Study Reinforce Vorasidenib's Potential to Change the Treatment Paradigm for IDH-Mutant Diffuse Glioma

Retrieved on: 
Saturday, November 18, 2023

BOSTON, Nov. 18, 2023 /PRNewswire/ -- New data from Servier's clinical development program for vorasidenib in IDH-mutant diffuse glioma, presented at the 28th Annual Meeting of the Society for Neuro-Oncology (SNO) in Vancouver, Canada, showed that vorasidenib reduced tumor growth as measured by a blinded independent radiology committee. Additional data from the INDIGO study being presented at SNO include health-related quality of life data, indicating patients receiving vorasidenib experience preservation of quality of life, stable neurocognitive function, and seizure control, as well as translational data demonstrating vorasidenib's efficacy across IDH-mutant diffuse gliomas with various additional mutations.

Key Points: 
  • We are honored and excited at the prospect of ushering in a new era of targeted treatment options for patients living with this devastating disease."
  • The safety lead-in was conducted to determine the recommended combination dose for the recently initiated perioperative phase of the study.
  • In this phase, approximately 60 patients will be randomized to the combination treatment, vorasidenib 40 mg once-daily alone, or no treatment prior to surgery.
  • KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

Canapi Ventures Welcomes Tom Davis As New General Partner

Retrieved on: 
Wednesday, November 15, 2023

WASHINGTON, Nov. 15, 2023 /PRNewswire/ -- Canapi Ventures, the fintech venture capital fund investing in early to growth stage financial services companies, today announced that Tom Davis has joined the company as a General Partner focused on leading growth stage equity investments. Davis will open Canapi's office in San Francisco and join the firm's investment committee. 

Key Points: 
  • WASHINGTON, Nov. 15, 2023 /PRNewswire/ -- Canapi Ventures, the fintech venture capital fund investing in early to growth stage financial services companies, today announced that Tom Davis has joined the company as a General Partner focused on leading growth stage equity investments.
  • Davis joins Canapi with close to two decades of experience in the financial services space, having worked with growth stage companies throughout his career at Morgan Stanley, General Atlantic, and Centana Growth Partners.
  • "Tom is the ideal fit for Canapi's multistage platform and overall growth investing efforts," said Walker Forehand, President and General Partner of Canapi Ventures.
  • As General Partner, Davis will lead Canapi's Bay Area operations and provide in-person engagement and connectivity with the firm's portfolio companies based on the West Coast.

Tevard Biosciences appoints Dr. Gregory Robinson as Chief Scientific Officer

Retrieved on: 
Monday, November 13, 2023

CAMBRIDGE, Mass., Nov. 13, 2023 /PRNewswire/ -- Tevard Biosciences , Inc., the pioneer of tRNA-based therapies and other mRNA-modulating treatments for genetic diseases, announced today that it has appointed Dr. Gregory Robinson as Chief Scientific Officer.

Key Points: 
  • CAMBRIDGE, Mass., Nov. 13, 2023 /PRNewswire/ -- Tevard Biosciences , Inc., the pioneer of tRNA-based therapies and other mRNA-modulating treatments for genetic diseases, announced today that it has appointed Dr. Gregory Robinson as Chief Scientific Officer.
  • Dr. Robinson brings extensive leadership experience with research and clinical development.
  • "Dr. Robinson has a long track record of success in translating innovative science into new medicines across therapeutic areas and modalities," said Tevard CEO and co-founder Daniel Fischer.
  • from Macalester College, a Ph.D. from Boston University, and completed postdoctoral studies at the Dana Farber Cancer Institute, Harvard Medical School.

Pan-Mass Challenge Donates Unprecedented $72 Million to Dana-Farber Cancer Institute

Retrieved on: 
Monday, November 13, 2023

BOSTON, Nov. 13, 2023 /PRNewswire/ -- Today, the Pan-Mass Challenge (PMC), the world's single most successful athletic fundraiser, announced its largest gift ever for cancer research, treatment, and care at the world-renowned Dana-Farber Cancer Institute, a record-breaking $72 million. This impressive gift will bring the PMC's total contributions to $972 million since 1980, positioning the organization to cross a monumental $1 billion in cumulative fundraising for the Institute in 2024.

Key Points: 
  • BOSTON, Nov. 13, 2023 /PRNewswire/ -- Today, the Pan-Mass Challenge (PMC), the world's single most successful athletic fundraiser, announced its largest gift ever for cancer research, treatment, and care at the world-renowned Dana-Farber Cancer Institute , a record-breaking $72 million.
  • This impressive gift will bring the PMC's total contributions to $972 million since 1980, positioning the organization to cross a monumental $1 billion in cumulative fundraising for the Institute in 2024.
  • "Our riders continue to expand the very definition of what a bike-a-thon, and a bicycle, was really meant to do!
  • When the PMC began in 1980, the five-year relative survival rate for cancer was 50 percent, and today, it's more than 65 percent.

EQS-News: invIOs and Dana-Farber Cancer Institute start collaboration to study novel small molecule INV501 for treatment of glioblastoma

Retrieved on: 
Friday, December 15, 2023

Preclinical study will be conducted by Dr. David Reardon’s research group

Key Points: 
  • Preclinical study will be conducted by Dr. David Reardon’s research group
    Vienna, Austria and Boston, MA USA, 9 November 2023: invIOs GmbH (“invIOs”), a privately held biotechnology company developing novel therapies for cancer, and Dana-Farber Cancer Institute have entered into a preclinical research collaboration to evaluate invIOs’ small molecule INV501 as a potential treatment for glioblastoma.
  • The collaboration will be led by David Reardon, MD, Clinical Director, Center for Neuro-Oncology at the Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School.
  • Dr. Reardon is a world-renowned expert in brain cancer, particularly glioblastoma research and treatment.
  • Among these, some compounds can cross the blood-brain barrier and enter the glioblastoma micro-environment to initiate anti-tumoral immune reactions.

invIOs and Dana-Farber Cancer Institute start collaboration to study novel small molecule INV501 for treatment of glioblastoma

Retrieved on: 
Thursday, November 9, 2023

Preclinical study will be conducted by Dr. David Reardon’s research group

Key Points: 
  • Preclinical study will be conducted by Dr. David Reardon’s research group
    VIENNA, Austria and BOSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- invIOs GmbH (“invIOs”), a privately held biotechnology company developing novel therapies for cancer, and Dana-Farber Cancer Institute have entered into a preclinical research collaboration to evaluate invIOs’ small molecule INV501 as a potential treatment for glioblastoma.
  • The collaboration will be led by David Reardon, MD, Clinical Director, Center for Neuro-Oncology at the Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School.
  • Dr. Reardon is a world-renowned expert in brain cancer, particularly glioblastoma research and treatment.
  • After seeing the initial promising preclinical data on INV501 in solid tumors presented by invIOs, we are excited to test this small molecule that crosses the blood-brain barrier in glioblastoma models.